D.E. Shaw & Co
TBPH icon

D.E. Shaw & Co’s Theravance Biopharma TBPH Stock Holding History

D.E. Shaw & Co’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.5M Sell
954,042
-305,899
-24% -$5.41M 0.01% 1316
2025
Q4 		$23.6M Buy
1,259,941
+50,629
+4% +$840K 0.01% 1150
2025
Q3 		$17.7M Buy
1,209,312
+207,546
+21% +$2.62M 0.01% 1266
2025
Q2 		$11M Buy
1,001,766
+81,464
+9% +$792K 0.01% 1422
2025
Q1 		$8.22M Buy
920,302
+86,359
+10% +$804K 0.01% 1537
2024
Q4 		$7.85M Buy
833,943
+69,178
+9% +$629K 0.01% 1654
2024
Q3 		$6.16M Buy
764,765
+6,685
+0.9% +$57.9K 0.01% 1782
2024
Q2 		$6.43M Sell
758,080
-23,505
-3% -$212K 0.01% 1660
2024
Q1 		$7.01M Sell
781,585
-69,623
-8% -$645K 0.01% 1647
2023
Q4 		$9.57M Buy
851,208
+161,647
+23% +$1.63M 0.01% 1400
2023
Q3 		$5.95M Sell
689,561
-24,553
-3% -$237K 0.01% 1674
2023
Q2 		$7.39M Sell
714,114
-300,879
-30% -$3.32M 0.01% 1586
2023
Q1 		$11M Sell
1,014,993
-557,657
-35% -$5.9M 0.01% 1284
2022
Q4 		$17.6M Sell
1,572,650
-14,548
-0.9% -$153K 0.02% 1007
2022
Q3 		$16.1M Buy
1,587,198
+206,801
+15% +$1.94M 0.02% 996
2022
Q2 		$12.5M Buy
1,380,397
+141,355
+11% +$1.3M 0.01% 1205
2022
Q1 		$11.8M Buy
1,239,042
+362,579
+41% +$3.55M 0.01% 1452
2021
Q4 		$9.68M Buy
876,463
+456,412
+109% +$3.98M 0.01% 1696
2021
Q3 		$3.11M Buy
+420,051
New +$4.7M ﹤0.01% 2597
2021
Q2 		– Sell
-56,014
Closed -$1.14M – 5012
2021
Q1 		$1.14M Buy
56,014
+20,954
+60% +$398K ﹤0.01% 3018
2020
Q4 		$623K Sell
35,060
-33,971
-49% -$610K ﹤0.01% 3286
2020
Q3 		$1.02M Sell
69,031
-5,993
-8% -$112K ﹤0.01% 2841
2020
Q2 		$1.57M Buy
75,024
+66,073
+738% +$1.7M ﹤0.01% 2598
2020
Q1 		$207K Buy
+8,951
New +$224K ﹤0.01% 3633
2019
Q3 		– Sell
-18,539
Closed -$375K – 4012
2019
Q2 		$303K Sell
18,539
-16,332
-47% -$331K ﹤0.01% 3310
2019
Q1 		$791K Sell
34,871
-40,163
-54% -$1.02M ﹤0.01% 2737
2018
Q4 		$1.92M Buy
75,034
+23,885
+47% +$645K ﹤0.01% 2184
2018
Q3 		$1.67M Buy
51,149
+14,971
+41% +$408K ﹤0.01% 2331
2018
Q2 		$821K Sell
36,178
-36,691
-50% -$871K ﹤0.01% 2820
2018
Q1 		$1.77M Sell
72,869
-14,715
-17% -$404K ﹤0.01% 2126
2017
Q4 		$2.44M Sell
87,584
-3,264
-4% -$96.6K ﹤0.01% 1993
2017
Q3 		$3.11M Sell
90,848
-87,859
-49% -$2.87M ﹤0.01% 1730
2017
Q2 		$7.12M Buy
178,707
+72,315
+68% +$2.78M 0.01% 1099
2017
Q1 		$3.92M Sell
106,392
-14,045
-12% -$449K 0.01% 1442
2016
Q4 		$3.84M Buy
120,437
+41,132
+52% +$1.28M 0.01% 1509
2016
Q3 		$2.87M Buy
79,305
+22,226
+39% +$619K 0.01% 1658
2016
Q2 		$1.29M Sell
57,079
-230,991
-80% -$4.99M ﹤0.01% 2245
2016
Q1 		$5.42M Sell
288,070
-122,057
-30% -$2M 0.01% 1215
2015
Q4 		$6.72M Sell
410,127
-280
-0.1% -$4.44K 0.01% 1212
2015
Q3 		$4.51M Sell
410,407
-40,369
-9% -$514K 0.01% 1477
2015
Q2 		$5.87M Buy
450,776
+6,745
+2% +$105K 0.01% 1342
2015
Q1 		$7.7M Sell
444,031
-196,608
-31% -$3.6M 0.01% 1116
2014
Q4 		$9.56M Sell
640,639
-48,695
-7% -$848K 0.01% 1142
2014
Q3 		$15.9M Buy
689,334
+249,142
+57% +$7.23M 0.02% 816
2014
Q2 		$14M Buy
+440,192
New +$13.3M 0.02% 880

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co's TBPH Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Theravance Biopharma (TBPH) stake by 24% in Q1 2026, selling an estimated $5.41M and leaving 954,042 shares worth $15.5M. The position accounts for 0.01% of the portfolio, ranked #1316.

D.E. Shaw & Co first reported a position in TBPH in Q2 2014 and has held it in 45 quarters since. The position peaked at $23.6M in Q4 2025. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • D.E. Shaw & Co held 954,042 shares of Theravance Biopharma worth $15.5M as of Q1 2026.
  • D.E. Shaw & Co sold 305,899 Theravance Biopharma shares in Q1 2026, an estimated $5.41M.
  • Theravance Biopharma made up 0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1316 holding.
  • D.E. Shaw & Co first reported a position in Theravance Biopharma in Q2 2014 and has held it in 45 quarters since.
  • D.E. Shaw & Co's Theravance Biopharma position peaked at $23.6M in Q4 2025.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.